Emerging treatments

Tumor necrosis factor (TNF)-alpha inhibitors

Mild elevations of TNF have been identified in the serum of ReA patients compared with controls.[72] Observational data suggest clinical benefit among ReA patients receiving TNF-alpha inhibitors; prospective randomized controlled trials are required.[73][74][75][76][77] There is some evidence to suggest TNF-alpha inhibitors do not reactivate the infective trigger in patients with ReA.[59]

Antibiotics

Several prospective randomized controlled trials have indicated that antibiotic therapy may be of benefit in patients with postchlamydial ReA.[78][46][79][80] However, a systematic review and meta-analysis found that antibiotic treatment had no significant effect on remission of ReA triggered by chlamydial infection.[81] Heterogeneity in trial results was reported and may have been attributable to differences in study design.[81] There is no data to suggest that long-term antibiotics have any therapeutic effect in the treatment of postenteric infection. Further high quality prospective RCTs are needed to confirm the role of antibiotic therapy in the management of postchlamydial ReA.

Use of this content is subject to our disclaimer